Project Grant HT94252410204
Award Date 4/1/24
Completion Date 3/31/28
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
- This federal Project Grant award of $1,442,061.00, awarded on April 1, 2024 by the Defense Health Agency, supports research under the Military Medical Research and Development program (CFDA 12.420) to investigate the role of podocyte ceramide synthase 6 in focal segmental glomerulosclerosis (FSGS). The primary awardee, the University of Texas Health Science Center at San Antonio, will conduct basic, translational, and clinical research to determine how genetic and toxin-induced FSGS affects...
- The University of Texas Health Science Center of San Antonio (UTHSCSA) received a $978,159 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into purinergic receptor antagonist therapeutics for treating metastatic renal cancer from July 1, 2023 through June 30, 2026. As the prime awardee, UTHSCSA will conduct research to develop medical solutions for cancer on the battlefield and...
- The Department of the Army Medical Command awarded $2,449,816 under the Military Medical Research and Development federal grant program (CFDA 12.420) to the University of Nebraska Medical Center for the period of April 1, 2022 through March 31, 2026. The award will support the development of a macromolecular dexamethasone prodrug for the treatment of focal segmental glomerulosclerosis (FSGS). As the sub-awardee, the University of Nebraska Medical Center will leverage its expertise in...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,565,298.00 to The University of Texas Health Science Center at San Antonio (UTHSCSA) to conduct research targeting the METTL3 gene to overcome drug resistance in metastatic clear cell renal cell carcinoma. The award period runs from September 1, 2025 to August 31, 2029. As a prominent Hispanic-serving academic medical center, UTHSCSA has an extensive portfolio...
- This federal Project Grant award of $1,640,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at The University of Texas Southwestern Medical Center (UT Southwestern) aimed at investigating the therapeutic parameters and mechanism of action of anti-miR-17 drugs in autosomal dominant polycystic kidney disease (ADPKD). The award period runs from April 1, 2025, to March 31, 2029. UT Southwestern, a...
- The Department of the Army Medical Command awarded a $2,455,660 project grant to Beth Israel Deaconess Medical Center, Inc. (doing business as Bidmc) to support research on "TRANSCRIPTION FACTORS AS THERAPEUTIC TARGETS IN FOCAL SEGMENTAL GLOMERULAR SCLEROSIS." The period of performance for this award is from September 30, 2022 through September 29, 2026. The grant is being funded through the Military Medical Research and Development program (CFDA 12.420). This program aims to transform...
- The University of Pittsburgh was awarded a $2,077,852 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 2022 through August 2025 to study the pros and cons of NRF2 in focal segmental glomerulosclerosis (FSGS) pathogenesis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
- The University of Texas Health Science Center at San Antonio (UTHSCSA) received a $1,907,470 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) on July 15, 2025. The award will fund a randomized clinical trial for "SWALLOWFIT: AN EXERCISE PROGRAM FOR US SERVICE MEMBERS, VETERANS, AND FAMILY WITH PARKINSON'S DISEASE" over a 3-year period, with a completion date of July 14, 2028. The project aims to develop and evaluate an...
- The University of Texas Health Science Center at San Antonio (UTHSCSA) was awarded a $1,560,218 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "REDUCING AGGRESSION IN MILITARY PERSONNEL: A RANDOMIZED CLINICAL TRIAL," will fund a research project aimed at developing innovative solutions to address aggressive behavior in military personnel. The project will take place over a 4-year period...
- This $1,872,750 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by The University of Texas Health Science Center at San Antonio (UTHSCSA) to investigate selisistat as an anti-prostate cancer agent for the treatment of prostate cancer. The award has a performance period from June 1, 2025 to May 31, 2028. The Military Medical Research and Development program funds advanced biomedical research to transform...